Curcumin in Combination With Mesalamine Induces Remission in Patients With Mild-to-Moderate Ulcerative Colitis in a Randomized Controlled Trial

Clinical Gastroenterology and Hepatology

Volumn 13, Issue 8, 2015, Pages 1444-1449.e1

  Lang, Alon ^a   Salomon, Nir ^a   Wu, Justin C Y ^b   Kopylov, Uri ^a   Lahat, Adi ^a   Har Noy, Ofir ^a   Ching, Jessica Y L ^b   Cheong, Pui Kuan ^b   Avidan, Benjamin ^a   Gamus, Dorit ^a   Kaimakliotis, Ioannis ^c   Eliakim, Rami ^a   Ng, Siew C ^b   Ben Horin, Shomron ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^c Central IBD Clinic   (Cyprus)

Author keywords

Clinical trial; IBD; Inflammatory bowel disease; Phytochemical

Indexed keywords

AZATHIOPRINE; CURCUMIN; MERCAPTOPURINE; MESALAZINE; PLACEBO; NONSTEROID ANTIINFLAMMATORY AGENT;

ABNORMAL FECES; ADD ON THERAPY; ADULT; AGED; ARTICLE; BLOATING; CLINICAL ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; ENDOSCOPY; FEMALE; HUMAN; INTENTION TO TREAT ANALYSIS; MALE; MULTICENTER STUDY; NAUSEA; RANDOMIZED CONTROLLED TRIAL; REMISSION; TREATMENT OUTCOME; TREATMENT RESPONSE; ULCERATIVE COLITIS; UNSPECIFIED SIDE EFFECT; ADOLESCENT; ADVERSE EFFECTS; CLINICAL TRIAL; COLITIS, ULCERATIVE; COMBINATION DRUG THERAPY; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PROCEDURES; YOUNG ADULT;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; COLITIS, ULCERATIVE; CURCUMIN; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HUMANS; MALE; MESALAMINE; MIDDLE AGED; PLACEBOS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84937523422     PISSN: 15423565     EISSN: 15427714     Source Type: Journal    
DOI: 10.1016/j.cgh.2015.02.019     Document Type: Article

References (25)

1. Dignass A., Lindsay J.O., Sturm A., et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management. J Crohns Colitis 2012, 6:991-1030.
2. Marteau P., Probert C.S., Lindgren S., et al. Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: a randomised, double blind, placebo controlled study. Gut 2005, 54:960-965.
3. Gupta S.C., Kismali G., Aggarwal B.B. Curcumin, a component of turmeric: from farm to pharmacy. BioFactors (Oxford, England) 2013, 39:2-13.
4. Midura-Kiela M.T., Radhakrishnan V.M., Larmonier C.B., et al. Curcumin inhibits interferon-gamma signaling in colonic epithelial cells. Am J Physiol Gastrointest Liver Physiol 2012, 302:G85-G96.
5. Larmonier C.B., Midura-Kiela M.T., Ramalingam R., et al. Modulation of neutrophil motility by curcumin: implications for inflammatory bowel disease. Inflamm Bowel Dis 2011, 17:503-515.
6. Venkataranganna M.V., Rafiq M., Gopumadhavan S., et al. NCB-02 (standardized Curcumin preparation) protects dinitrochlorobenzene-induced colitis through down-regulation of NFkappa-B and iNOS. World J Gastroenterol 2007, 13:1103-1107.
7. Sugimoto K., Hanai H., Tozawa K., et al. Curcumin prevents and ameliorates trinitrobenzene sulfonic acid-induced colitis in mice. Gastroenterology 2002, 123:1912-1922.
8. Hanai H., Iida T., Takeuchi K., et al. Curcumin maintenance therapy for ulcerative colitis: randomized, multicenter, double-blind, placebo-controlled trial. Clin Gastroenterol Hepatol 2006, 4:1502-1506.
9. Higgins P.D., Schwartz M., Mapili J., et al. Is endoscopy necessary for the measurement of disease activity in ulcerative colitis?. Am J Gastroenterol 2005, 100:355-361.
10. Walmsley R.S., Ayres R.C., Pounder R.E., et al. A simple clinical colitis activity index. Gut 1998, 43:29-32.
11. Schroeder K.W., Tremaine W.J., Ilstrup D.M. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis: a randomized study. N Engl J Med 1987, 317:1625-1629.
12. D'Haens G., Sandborn W.J., Feagan B.G., et al. A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology 2007, 132:763-786.
13. Mulder C.J., Fockens P., Meijer J.W., et al. Beclomethasone dipropionate (3 mg) versus 5-aminosalicylic acid (2 g) versus the combination of both (3 mg/2 g) as retention enemas in active ulcerative proctitis. Eur J Gastroenterol Hepatol 1996, 8:549-553.
14. Tursi A., Brandimarte G., Papa A., et al. Treatment of relapsing mild-to-moderate ulcerative colitis with the probiotic VSL#3 as adjunctive to a standard pharmaceutical treatment: a double-blind, randomized, placebo-controlled study. Am J Gastroenterol 2010, 105:2218-2227.
15. Turner D., Seow C.H., Greenberg G.R., et al. A systematic prospective comparison of noninvasive disease activity indices in ulcerative colitis. Clin Gastroenterol Hepatol 2009, 7:1081-1088.
16. Higgins P.D., Schwartz M., Mapili J., et al. Patient defined dichotomous end points for remission and clinical improvement in ulcerative colitis. Gut 2005, 54:782-788.
17. Singla V., Pratap Mouli V., Garg S.K., et al. Induction with NCB-02 (curcumin) enema for mild-to-moderate distal ulcerative colitis: a randomized, placebo-controlled, pilot study. J Crohns Colitis 2014, 8:208-214.
18. Singh S., Aggarwal B.B. Activation of transcription factor NF-kappa B is suppressed by curcumin (diferuloylmethane) [corrected]. J Biol Chem 1995, 270:24995-25000.
19. Chen D., Nie M., Fan M.W., et al. Anti-inflammatory activity of curcumin in macrophages stimulated by lipopolysaccharides from Porphyromonas gingivalis. Pharmacology 2008, 82:264-269.
20. Chan M.M. Inhibition of tumor necrosis factor by curcumin, a phytochemical. Biochem Pharmacol 1995, 49:1551-1556.
21. Salh B., Assi K., Templeman V., et al. Curcumin attenuates DNB-induced murine colitis. Am J Physiol Gastrointest Liver Physiol 2003, 285:G235-G243.
22. Larmonier C.B., Uno J.K., Lee K.M., et al. Limited effects of dietary curcumin on Th-1 driven colitis in IL-10 deficient mice suggest an IL-10-dependent mechanism of protection. Am J Physiol Gastrointest Liver Physiol 2008, 295:G1079-G1091.
23. Usharani P., Mateen A.A., Naidu M.U., et al. Effect of NCB-02, atorvastatin and placebo on endothelial function, oxidative stress and inflammatory markers in patients with type 2 diabetes mellitus: a randomized, parallel-group, placebo-controlled, 8-week study. Drugs R D 2008, 9:243-250.
24. Baum L., Lam C.W., Cheung S.K., et al. Six-month randomized, placebo-controlled, double-blind, pilot clinical trial of curcumin in patients with Alzheimer disease. J Clin Psychopharmacol 2008, 28:110-113.
25. Cruz-Correa M., Shoskes D.A., Sanchez P., et al. Combination treatment with curcumin and quercetin of adenomas in familial adenomatous polyposis. Clin Gastroenterol Hepatol 2006, 4:1035-1038.